How common is PoTS in long COVID?
Autonomic dysfunction has emerged as one of the most prevalent and clinically significant manifestations of long COVID. Multiple studies have identified PoTS or features consistent with orthostatic intolerance in a substantial proportion of people with persistent post-COVID symptoms.[1]
The COVID-19 pandemic has substantially increased the overall prevalence of PoTS. Estimates suggest hundreds of thousands of people in the UK may have developed post-COVID PoTS, representing a significant and ongoing public health challenge that primary care is at the forefront of managing.
Why does COVID-19 cause PoTS?
Several mechanisms have been proposed to explain how acute SARS-CoV-2 infection leads to persistent autonomic dysfunction. The evidence suggests that post-COVID PoTS is likely multifactorial — different patients may have different dominant mechanisms — and this may have implications for which treatments are most effective in individual cases.[2]
| Proposed mechanism | Evidence | Implication |
|---|---|---|
| Autoimmune autonomic dysfunction | Autoantibodies against adrenergic and muscarinic receptors found at elevated titres in post-COVID PoTS. May result from molecular mimicry between SARS-CoV-2 proteins and host autonomic receptors.[4] | Suggests immunomodulatory approaches may benefit a subset of patients. Research ongoing. |
| Reduced plasma volume and hypovolaemia | Post-COVID patients with PoTS consistently show reduced circulating blood volume, similar to classical PoTS — possibly exacerbated by prolonged illness, reduced activity, and poor oral intake during acute phase.[1] | Supports aggressive fluid and salt loading as first-line management. |
| Small fibre neuropathy | Evidence of small fibre nerve damage in some post-COVID patients, including reduced intraepidermal nerve fibre density on skin biopsy, suggesting an inflammatory or immune-mediated neuropathy.[4] | Neuropathic PoTS management approaches (volume expansion, compression) are appropriate. |
| Sympathetic activation and hyperadrenergic state | Elevated standing noradrenaline and a hyperadrenergic pattern have been documented in a subset of post-COVID PoTS patients.[2] | Beta-blockers or ivabradine may be particularly helpful in this subtype. |
| Deconditioning and prolonged immobility | Acute COVID illness, hospitalisation, and self-isolation contribute to deconditioning, which worsens any underlying autonomic vulnerability.[1] | Exercise rehabilitation is important — with important caveats regarding PEM (see below). |
How does post-COVID PoTS differ from classical PoTS?
While the core diagnostic features are the same — postural tachycardia of ≥30 bpm with orthostatic symptoms — post-COVID PoTS has several clinically relevant differences from classical PoTS that affect both assessment and management.
| Feature | Classical PoTS | Post-COVID PoTS |
|---|---|---|
| Demographics | Predominantly women 15–50 | Broader — men and older adults more represented |
| Onset | Often gradual; may follow viral illness | Clearly temporally linked to COVID-19 infection |
| ME/CFS features | Present in ~25–50% | Present in up to ~38% of post-COVID PoTS[3] |
| Autoimmune features | In a minority | More prominent; autoantibodies more frequently found[4] |
| Coexisting symptoms | Variable; fatigue, brain fog common | Often multisystem — respiratory, neurological, cardiac symptoms alongside autonomic |
| Natural history | Chronic; often persistent without treatment | More variable; ~40% remission at 2 years; may improve more than classical[3] |
| Response to exercise | Good response to structured rehabilitation | Must screen for PEM first; if present, adapt carefully |
Diagnosing post-COVID PoTS
The diagnostic criteria for post-COVID PoTS are the same as for classical PoTS: a sustained heart rate rise of ≥30 bpm within 10 minutes of standing (≥40 bpm in adolescents), without significant orthostatic hypotension, accompanied by symptoms of orthostatic intolerance.[2] The post-COVID context is established by the clinical history.
When to consider post-COVID PoTS
- Symptoms of orthostatic intolerance (dizziness, palpitations, fatigue, brain fog on standing) beginning or significantly worsening within 3–6 months of a COVID-19 infection
- Persistent symptoms in a person with confirmed or probable long COVID
- Exercise intolerance or worsening on minimal exertion that has a postural component
- A broader long COVID symptom burden (breathlessness, cognitive difficulty, fatigue) alongside specific orthostatic symptoms
Managing post-COVID PoTS
The management framework for post-COVID PoTS follows the same principles as classical PoTS — non-pharmacological measures first, pharmacotherapy where needed — with two important additional considerations: the frequent coexistence of ME/CFS-type features, and the possibility of spontaneous improvement over time in some patients.
Non-pharmacological measures
- Fluid and salt loading — 2–3 litres fluid daily, 8–10 g salt. Often the most impactful initial intervention. Some patients notice rapid improvement.
- Compression garments — waist-high compression (20–30 mmHg). Safe and effective.
- Postural strategies — gradual position changes, counter-manoeuvres, head-of-bed elevation.
- Trigger avoidance — heat, large meals, alcohol, and prolonged standing worsen symptoms and should be managed as in classical PoTS.
Exercise — with important caveats
Two-year outcome data suggest that early exercise rehabilitation is associated with significantly better outcomes in post-COVID PoTS.[3] However, PEM must be screened for before any exercise programme is commenced. If PEM is present, pacing takes precedence. If PEM is absent, a recumbent-based, gradual rehabilitation programme (as for classical PoTS) is appropriate.
Pharmacotherapy
The same medication options used in classical PoTS apply — ivabradine, low-dose propranolol, fludrocortisone, midodrine — all off-label, with the same prescribing considerations. There is no specific pharmacological treatment for the post-COVID context at present, though research into immunomodulatory approaches is ongoing.[4]
What are the long-term outcomes?
Post-COVID PoTS appears to have a more variable natural history than classical PoTS, with a meaningful proportion of patients achieving remission — though a significant number remain substantially affected at two years.[3]
| Outcome at 2 years | Approximate proportion | Key predictors |
|---|---|---|
| Full or near-full symptomatic remission | ~40% | Early exercise rehabilitation, absence of ME/CFS features, younger age |
| Partial improvement — significant ongoing symptoms | ~25% | Variable; partial response to management |
| Persistent significant disability | ~35% | Coexisting ME/CFS, delayed diagnosis (>12 months), older age at onset[3] |
These data underline the importance of early identification and management — the window for intervention appears to matter, and patients who receive structured treatment early have better outcomes. For the subset with persistent significant disability, multidisciplinary input and specialist referral are important.